Bodhi Tree Biotechnology Inc
AI Executive Summary
AI-powered analysis of 10-Q filing content
Bodhi Tree Biotechnology shows severe deterioration with zero revenue in Q1 2025 versus $5,000 in Q1 2024, rapidly depleting cash reserves falling 57% to $47,366, and accelerating accumulated losses reaching $264,567. The company maintains high G&A expenses of $52,949 quarterly with no revenue generation, indicating potential going concern issues.
Red Flags Detected (6)
Complete revenue collapse from $5,000 to $0 year-over-year
Cash reserves depleted 57% in single quarter from $109,404 to $47,366
Accumulated deficit increased 25% to $264,567 in three months
3 more red flags detected
Key Takeaways
Company faces imminent liquidity crisis with less than one quarter of operating cash remaining
Business model appears broken with zero revenue generation despite continued operations
2 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.